Arrowhead Pharmaceuticals - Public Comps and Valuation Multiples

Arrowhead Pharmaceuticals Overview

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.

Founded

1989

HQ

Employees

609

Website

arrowheadpharma.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $713M

LTM EBITDA $35.1M

EV

$4.5B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Arrowhead Pharmaceuticals Financials

As of September 2025, Arrowhead Pharmaceuticals reported last 12-month revenue of $713M and EBITDA of $35.1M.

In the same period, Arrowhead Pharmaceuticals generated $712M in LTM gross profit and -$25.9M in net income.

See Arrowhead Pharmaceuticals valuation multiples based on analyst estimates

Arrowhead Pharmaceuticals P&L

In the most recent fiscal year, Arrowhead Pharmaceuticals reported revenue of $3.6M and EBITDA of -$562M.

Arrowhead Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Arrowhead Pharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$713M	XXX	$3.6M	XXX	XXX	XXX
Gross Profit	$712M	XXX	n/a	XXX	XXX	XXX
Gross Margin	100%	XXX	n/a	XXX	XXX	XXX
EBITDA	$35.1M	XXX	-$562M	XXX	XXX	XXX
EBITDA Margin	5%	XXX	-15813%	XXX	XXX	XXX
EBIT	$17.9M	XXX	-$601M	XXX	XXX	XXX
EBIT Margin	3%	XXX	-16927%	XXX	XXX	XXX
Net Profit	-$25.9M	XXX	-$599M	XXX	XXX	XXX
Net Margin	-4%	XXX	-16882%	XXX	XXX	XXX
Net Debt	XXX	XXX	$290M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Arrowhead Pharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $713M. EBITDA for the last twelve months was $35.1M. In the most recent fiscal year, Arrowhead Pharmaceuticals achieved $3.6M in revenue and -$562M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$713M	Analyst estimates available to subscribers	$3.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$712M	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	99.9% gross margin	Analyst estimates available to subscribers	NaN% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$35.1M	Analyst estimates available to subscribers	-$562M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	4.9% EBITDA margin	Analyst estimates available to subscribers	-15812.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$17.9M	Analyst estimates available to subscribers	-$601M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	2.5% EBIT margin	Analyst estimates available to subscribers	-16927.1% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$25.9M	Analyst estimates available to subscribers	-$599M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-3.6% net profit margin	Analyst estimates available to subscribers	-16882.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$290M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Arrowhead Pharmaceuticals

This financial data table provides comprehensive performance metrics for Arrowhead Pharmaceuticals, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Arrowhead Pharmaceuticals generated $713M in revenue over the last twelve months.
The company achieved $35.1M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $712M.
Net income over the last twelve months reached -$25.9M.

Fiscal Year Performance

In the most recent fiscal year, Arrowhead Pharmaceuticals reported $3.6M in total revenue.
Fiscal year EBITDA was -$562M.
The company maintained a gross profit margin of NaN% in the most recent fiscal year.
EBITDA margin for the fiscal year was -15812.8%.
Net profit margin reached -16882.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Arrowhead Pharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals has current market cap of $5.1B, and EV of $4.5B.

Market Cap Evolution

Arrowhead Pharmaceuticals Stock Data

As of October 17, 2025, Arrowhead Pharmaceuticals's stock price is $37.

See Arrowhead Pharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$4.5B	$5.1B	XXX	XXX	XXX	XXX	$-0.21

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Arrowhead Pharmaceuticals Valuation Multiples

Arrowhead Pharmaceuticals's trades at 24.4x EV/Revenue multiple, and -11.2x EV/EBITDA.

See valuation multiples for Arrowhead Pharmaceuticals and 15K+ public comps

Arrowhead Pharmaceuticals Financial Valuation Multiples

As of October 17, 2025, Arrowhead Pharmaceuticals has market cap of $5.1B and EV of $4.5B.

Equity research analysts estimate Arrowhead Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Arrowhead Pharmaceuticals has a P/E ratio of -196.2x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$5.1B	XXX	$5.1B	XXX	XXX	XXX
EV (current)	$4.5B	XXX	$4.5B	XXX	XXX	XXX
EV/Revenue	6.4x	XXX	24.4x	XXX	XXX	XXX
EV/EBITDA	129.3x	XXX	-11.2x	XXX	XXX	XXX
EV/EBIT	254.2x	XXX	-10.3x	XXX	XXX	XXX
EV/Gross Profit	6.4x	XXX	n/a	XXX	XXX	XXX
P/E	-196.2x	XXX	-11.3x	XXX	XXX	XXX
EV/FCF	18.0x	XXX	-11.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Arrowhead Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Arrowhead Pharmaceuticals Margins & Growth Rates

Arrowhead Pharmaceuticals's last 12 month revenue growth is -50%

Arrowhead Pharmaceuticals's revenue per employee in the last FY averaged $6K, while opex per employee averaged $1.0M for the same period.

Arrowhead Pharmaceuticals's rule of 40 is -200% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Arrowhead Pharmaceuticals's rule of X is -121% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Arrowhead Pharmaceuticals and other 15K+ public comps

Arrowhead Pharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	-50%	XXX	38%	XXX	XXX	XXX
EBITDA Margin	5%	XXX	-219%	XXX	XXX	XXX
EBITDA Growth	-1190%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-200%	XXX	-269%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-121%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$6K	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.0M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	14246%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	17027%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial